drugset
drugset / Trial / NCT05178342

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

NCT05178342 ↗

Phase 2 Terminated 38 enrolled University of Leipzig Curis, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Anemia in LR-MDS patients

Timeline

Start
2022-01-01
Primary completion
2024-07-31
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Emavusertib Small molecule 300 mg Oral

Indications

anemia myelodysplastic syndrome